618 related articles for article (PubMed ID: 32483657)
1. Formulation and Delivery Technologies for mRNA Vaccines.
Zeng C; Zhang C; Walker PG; Dong Y
Curr Top Microbiol Immunol; 2022; 440():71-110. PubMed ID: 32483657
[TBL] [Abstract][Full Text] [Related]
2. The Delivery of mRNA Vaccines for Therapeutics.
Nitika ; Wei J; Hui AM
Life (Basel); 2022 Aug; 12(8):. PubMed ID: 36013433
[TBL] [Abstract][Full Text] [Related]
3. mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer.
Malla R; Srilatha M; Farran B; Nagaraju GP
Mol Ther; 2024 Jan; 32(1):13-31. PubMed ID: 37919901
[TBL] [Abstract][Full Text] [Related]
4. The clinical progress and challenges of mRNA vaccines.
Yu MZ; Wang NN; Zhu JQ; Lin YX
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1894. PubMed ID: 37096256
[TBL] [Abstract][Full Text] [Related]
5. [New Hopes in Vaccine Technology: mRNA Vaccines].
Yılmaz E
Mikrobiyol Bul; 2021 Apr; 55(2):265-284. PubMed ID: 33882657
[TBL] [Abstract][Full Text] [Related]
6. mRNA vaccine designs for optimal adjuvanticity and delivery.
Mochida Y; Uchida S
RNA Biol; 2024 Jan; 21(1):1-27. PubMed ID: 38528828
[TBL] [Abstract][Full Text] [Related]
7. Delivery Strategies for mRNA Vaccines.
Ramachandran S; Satapathy SR; Dutta T
Pharmaceut Med; 2022 Feb; 36(1):11-20. PubMed ID: 35094366
[TBL] [Abstract][Full Text] [Related]
8. Current Developments and Challenges of mRNA Vaccines.
Chen J; Chen J; Xu Q
Annu Rev Biomed Eng; 2022 Jun; 24():85-109. PubMed ID: 35231177
[TBL] [Abstract][Full Text] [Related]
9. [mRNA vaccines for infectious diseases: research progress and applications].
Qin F; Ren N; Cheng W; Wei H
Sheng Wu Gong Cheng Xue Bao; 2023 Oct; 39(10):3966-3984. PubMed ID: 37877385
[TBL] [Abstract][Full Text] [Related]
10. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
Maruggi G; Zhang C; Li J; Ulmer JB; Yu D
Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823
[TBL] [Abstract][Full Text] [Related]
11. The Current Landscape of mRNA Vaccines Against Viruses and Cancer-A Mini Review.
Ladak RJ; He AJ; Huang YH; Ding Y
Front Immunol; 2022; 13():885371. PubMed ID: 35603213
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Characterization of mRNA-Loaded Poly(Beta Aminoesters) Nanoparticles for Vaccination Purposes.
Fornaguera C; Díaz-Caballero M; García-Fernandez C; Olmo L; Stampa-López Pinto M; Navalón-López M; Guerra-Rebollo M; Borrós S
J Vis Exp; 2021 Aug; (174):. PubMed ID: 34459811
[TBL] [Abstract][Full Text] [Related]
13. Advanced nanoscale delivery systems for mRNA-based vaccines.
Mobasher M; Ansari R; Castejon AM; Barar J; Omidi Y
Biochim Biophys Acta Gen Subj; 2024 Mar; 1868(3):130558. PubMed ID: 38185238
[TBL] [Abstract][Full Text] [Related]
14. Emergence of mRNA vaccines in the management of cancer.
Mohamad Razif MI; Nizar N; Zainal Abidin NH; Muhammad Ali SN; Wan Zarimi WNN; Khotib J; Susanti D; Mohd Jailani MT; Taher M
Expert Rev Vaccines; 2023; 22(1):629-642. PubMed ID: 37401128
[TBL] [Abstract][Full Text] [Related]
15. The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines.
Wei J; Hui AM
Cancer Treat Rev; 2022 Jun; 107():102405. PubMed ID: 35576777
[TBL] [Abstract][Full Text] [Related]
16. Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases.
Chung S; Lee CM; Zhang M
Nanoscale Horiz; 2022 Dec; 8(1):10-28. PubMed ID: 36260016
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in mRNA cancer vaccines.
Yao R; Xie C; Xia X
Hum Vaccin Immunother; 2024 Dec; 20(1):2307187. PubMed ID: 38282471
[TBL] [Abstract][Full Text] [Related]
18. mRNA delivery technologies: Toward clinical translation.
Gómez-Aguado I; Rodríguez-Castejón J; Beraza-Millor M; Rodríguez-Gascón A; Del Pozo-Rodríguez A; Solinís MÁ
Int Rev Cell Mol Biol; 2022; 372():207-293. PubMed ID: 36064265
[TBL] [Abstract][Full Text] [Related]
19. mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.
Matarazzo L; Bettencourt PJG
Front Immunol; 2023; 14():1172691. PubMed ID: 37168860
[TBL] [Abstract][Full Text] [Related]
20. Building a Better Silver Bullet: Current Status and Perspectives of Non-Viral Vectors for mRNA Vaccines.
Gu J; Xu Z; Liu Q; Tang S; Zhang W; Xie S; Chen X; Chen J; Yong KT; Yang C; Xu G
Adv Healthc Mater; 2024 Jan; 13(3):e2302409. PubMed ID: 37964681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
